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CEPHALEXIN: CLINICAL AND LABORATORY STUDIESt
Cephalexin, 7(D-a-amino-a-phenylactemomido)-3-methyl-3-cepham-4-car-
boxylic acid, is a semi-synthetic derivative of cephalosporin-C and has an
antibacterial spectrum similar to cephalothin, cephaloridine and cephalogly-
cine. It is the only cephalosporin antibiotic to give high drug concentrations
in both the serum and urine of human subjects after oral administration.1 It
differs from cephaloglycine which yields high urine concentrations but only
negligible serum concentrations following oral administration.!
The high serum levels attainable with cephalexin make it a promising
drug for the treatment of a variety of infections requiring oral therapy. The
present study examines the efficacy of the drug in such treatment. This re-
port describes the clinical response of 26 infections in 22 patients who were
treated with oral cephalexin and the in vitro sensitivity of a number of gram-
positive and gram-negative bacteria isolated from patients in the hospital.
METHODS
Clinical studies: Twenty-two patients, four male and eighteen female, at Yale-New
Haven Hospital and the West Haven Veterans Administration Hospital, received 25
courses of cephalexin for 26 separate infections. One patient was nine years old; the
others were adults. All patients or their guardians gave informed consent to the use
of an investigational drug.
Patients with urinary tract infections had urine cultures done prior to therapy, dur-
ing therapy, and four weeks after treatment was stopped. Urines for culture were ob-
tained by the clean catch method previously reported.' Significant bacteriuria was de-
fined as 100,000 colonies or more per milliliter of urine per species of bacteria.
A urinary tract infection was defined as the presence of significant bacteriuria on
two consecutive urine cultures in an asymptomatic patient, or as the presence of sig-
nificant bacteriuria on one culture in a patient with urinary tract symptoms. Urinary
infections were subdivided into three arbitrary categories. Patients with fever, signifi-
cant bacteriuria and flank tenderness were considered to have pyelonephritis. Patients
with significant bacteriuria accompanied by dysuria without fever or flank tenderness
were considered to have cystitis. Asymptomatic bacteriuria was defined as the occur-
rence of significant bacteriuria without other signs or symptoms of urinary tract in-
fections. All patients with a history of more than one clinical urinary tract infection
were given an intravenous pyelogram.
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Patients with skin infections or osteomyelitis had cultures done before treatment;
post therapy cultures were performed when possible.
Drug dosage and length of treatment were individualized on the basis of the patient's
general condition, renal function, and type of infection. Most patients were given 500
mg of cephalexin four times a day for twelve days. They were instructed to take the
drug an hour before meals and at bedtime.
Hematocrit, white blood cell count, blood urea nitrogen, bilirubin, serum glutamic-
oxaloacetic transaminase, alkaline phosphotase, cephalin flocculation, thymol turbidity
and routine urinalysis were done before, at intervals during, and after therapy in all
patients.
Clinical response to cephalexin was divided into five categories. Cures were defined
as the elimination of bacteriuria during, and for at least four weeks after, cephalexin
treatment, or the healing of skin lesions during treatment. Failures were defined as
persistence of bacteriuria with the pre-treatment pathogen during treatment or the lack
of healing of skin lesions with persistence of the pre-treatment pathogen. Relapses
were defined as the recurrence of bacteriuria with an organism of the same species as
the pre-treatment pathogen after eradication during treatment, or the clinical deteriora-
tion of an apparently healed skin lesion associated with infection caused by the pre-
treatment organism. Reinfections were defined as the occurrence of bacteriuria with an
organism different from the pre-treatment pathogen, either during or within four weeks
after treatment, or the clinical deterioration of a skin lesion associated with infection
by a new species of bacteria. Indeterminate cases were those in which inadequate cul-
tural or clinical data prevented inclusion in one of the above categories.
Laboratory studies. Gram-negative bacteria (148 strains) and gram-positive bacteria
(103 strains) isolated from patients with clinical infections were studied. Organisms
were collected from the clinical bacteriology laboratory, subcultured and reidentified
according to the scheme of Schaub et al.' in our research bacteriology laboratory be-
fore antibiotic sensitivity tests were performed.
All organisms were tested against cephalexin by both tube dilution and antibiotic
disc methods. Each bacterial strain was tested against cephalexin discs containing
30 gg of antibiotic. As previously reported,' a modification of the single disc method
of Kirby et al.' and Turck, Lindemeyer, and Petersdorf7 was used in the present study.
Tube dilution sensitivities were also performed as previously described' except that
nutrient broth at pH 6.6 was used to stabilize the antibiotic, thus permitting accurate
interpretation of the minimum inhibitory and minimum bactericidal concentrations 24
hours after incubation at 37°C. Nutrient agar at the same pH was also used for the
single disc cephalexin sensitivity studies.
RESULTS
Twenty-two patients received 25 courses of therapy for 26 infections as
summarized in Table 1. One patient (EV) was treated three times and
another (RN) was treated twice; one patient (JG) received a single course
of therapy for concurrent infection of the skin and the urinary tract.
Of the 26 infections, 22 involved the urinary tract. Results of the treat-
ment of these 22 infections occurring in 19 patients are classified in Table 2
according to the presence or absence of structural urinary tract abnormali-
ties. Ten of the 22 urinary tract infections occurred in patients with no evi-
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TABLE 1. RESULTS OF 26 COURSES OF CEPHALEXIN THERAPY IN 22 PATIENTS
WITH INFECTIONS
Daily
Course dose Outcome of
Patient Age Disease Pathogen (days) (gms) therapy
84
55
58
55
58
9
22
29
Bacteriuria
to
Pt
Pt
.,
Pt
Cystitis
of
19 "
37 "
25 "
25 "
26 "
23 "
39 "
56 "
46 "
46 "
46 "
34 Pyelonephritis
36
51
I
55 Skin infection
58
31
43 Osteomyelitis
Klebsiella
P. vulgaris
P. mirabilis
Klebsiella
E. coli
E. coli
E. coli
E. coli
Klebsiella
P. mirabilis
E. coli
E. coli
E. coli
Enterobacter
E. coli
Klebsiella
E. coli
Enterobacter
E. coli
Enterococcus
E. coli
Klebsiella
P. mirabilis
Unknown
Peptococcus
P. mirabilis
S. autreus
12 1 Cure
46 2 Relapse
12 2 Relapse
12 2 Relapse
22 2 Indeterminate
90 1 Reinfection
12 2 Cure
16 1 Reinfection
6 2 Cure
129 2 Relapse
10 2 Relapse
16 2 Cure
12 2 Cure
12 2 Cure
12 2 Reinfection
12 2 Cure
295 2 Reinfection
72 2 Reinfection
235 1-2 Reinfection
12 2 Cure
30 2 Reinfection
1 Relapse
46 2 Cure
42 2 Cure
60 2 Cure
107 2 Indeterminate
TABLE 2. RESULTS OF CEPHALEXIN TREATMENT IN 19 PATIENTS
WITH 22 INFECTIONS OF THE URINARY TRACT
Rein- Indeter-
Infections Cure Failure Relapse fection minate
Normal urinary tract
Cystitis 6 5 0 1 0 0
Pyelonephritis 1 1 0 0 0 0
Asymptomatic bacteriuria 3 1 0 1 0 1
Abnormnal urinary tract
Cystitis 7 1 0 1 5 0
Pyelonephritis 2 0 0 1 1 0
Asymptomatic bacteriuria 3 0 0 2 1 0
Total 22 8 0 6 7 1
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1 LM
2 JG-1
3 FVP
4 TZ
5 IM
6 CW
7 BL
8 BP
9 JC
10 LN
11 RN
12 RN-2
13 JT
14 NI
15 AG
16 DH
17 EV-1
18 EV-2
19 EV-3
20 SM
21 EW
22 BS
23 JG-2
24 FL
25 SR
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dence of structural urinary tract abnormalities. Most of these patients were
young women with acute cystitis. Seven of these 10 patients were cured
with cephalexin treatment. One patient who relapsed was cured with a
second course of therapy. One patient who is classified as indeterminate was
abacteriuric on treatment but was unavailable for follow-up. One patient
with chronic bacteriuria relapsed after treatment. Only one of the 12 infec-
tions in patients with anatomic abnormalities of the urinary tract was cured
with cephalexin treatment. Four relapses occurred after treatment was
stopped, and the other seven were reinfected during or after treatment. No
patient, regardless of the state of his urinary tract, was a treatment failure,
as defined above.
E. coli was responsible for seven of the ten infections in patients with
normal urinary tracts but caused only three infections among the twelve
patients with abnormal urinary tracts. In the latter group, infections were
more commonly caused by Klebsiella, Enterobacter, Proteus vulgaris, Pro-
teus mirabilis and enterococcus species.
The three patients with skin infections all responded to treatment with a
daily dose of two grams of cephalexin for two to six weeks. One of these
infections was caused by an anaerobic micrococcus, one by Proteus mirabilis
and one, in a patient with a renal transplant, was nonspecific and grew no
organisms on culture.
The single case of osteomyelitis was caused by Staphylococcus aureus.
This infection was treated with intravenous cephalothin for two weeks, fol-
lowed by oral cephalexin for 6 weeks in a dose of two grams per day. Be-
cause the staphylococcus could not be recovered from the osteomyelitis
lesion after cephalothin therapy was begun, the effect of cephalexin on the
outcome of this patient's infection could not be accurately evaluated and is
recorded as indeterminate even though the infection healed without incident.
One patient (JG) developed elevated bilirubin and serum glutamic oxalo-
acetic transaminase while receiving cephalexin. At that time he was also re-
ceiving azathioprin, which has been known to cause such abnormalities.8
This patient's liver function studies remained abnormal until his death,
which occurred a year after cephalexin was stopped but while he was still
receiving azathioprin. No other patients developed abnormal values of liver
function studies.
Two women developed symptomatic Candida vaginitis during cephalexin
therapy. This condition resolved with the cessation of cephalexin treatment
and local use of nystatin.
Three patients experienced mild, transient nausea while taking cephalexin.
No patient had diarrhea. Renal dysfunction or peripheral blood abnormali-
ties were not noted in any of the patients.
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Laboratory studies. The bacteriostatic and bactericidal activity of cepha-
lexin against 104 bacterial cells of various organisms is shown in Figures 1,
2 and 3. All strains of Staphylococcus aureus and most strains of Staphylo-
coccus albus, E. coli, Klebsiella and indole negative Proteus were sensitive
to 12.5 jug/ml. or less of cephalexin. In contrast, most strains of Pseudo-
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FIG. 1. Susceptibility of four species of gram-negative bacteria to increasing con-
centrations of cephalexin.
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monas, Enterobacter, indole positive Proteus, and Serratia and enterococcus
were resistant to concentrations of cephalexin in the range of 50 to 100
jLg/ml.
The diameter of the zone of inhibition of bacterial growth around a 30 ,ug
cephalexin disc was compared with the tube dilution sensitivity of a number
of strains of gram-positive and gram-negative bacteria by the method used
in this laboratory and reported previously.! The results of this comparison
are shown in Figs. 4 and 5. Since the 6 mm. diameter of the antibiotic disc
is included in the final reading, a zone size of 6 mm. indicates no inhibition
of bacterial growth. A zone of inhibition of 16 mm. or more correlated well
with a minimal inhibitory concentration of 12.5 Ag/ml. or less of cephalexin
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FIG. 2. Susceptibility of three species of gram-negative bacteria to increasing con-
centrations of cephalexin.
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in all species tested except indole negative Proteus and Klebsiella. Among
the indole negative Proteus, 9 of the 19 strains tested gave a zone size of
less than 16 mm. in spite of being inhibited by 12.5 ,ug/ml. of cephalexin.
Six of 22 strains of Klebsiella gave zone sizes greater than 16 mm. although
they required 25 jug/ml. of cephalexin to inhibit their growth.
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DISCUSSION
The oral administration of 500 mg. of cephalexin gives a peak serum level
of about 18 jug/ml.V This is 75%o of the serum level achieved with the same
dose of parenteral cephaloridine and nearly twice that achieved by intra-
MIC CEPHALEXIN VS ZONE OF INHIBITION OF 3Opg DISC
0
E. coil
(22)
1, I I . I I
0 0
_ Enterobacter
(20)
11 1 11 1 1 1 II II
0
KIebsI@llo
(22)
,, ., .., .. 1 1
Pseudomonas
_ (21)
*
0 0
_ Serraoti
(23) _
i 1- I I20--
PI&
I
i
0
I
0
. 0-11m" 0
Proteus
* indole neg (09)
* indole pos (20)
1 1 1 1 1 1 1 1 1 1 I1
6 10 14 18 22 26 3034 6 10 14 16 22 26 30 34
ZONE o0 INHIBITION o0 '30M CEPHALEXIN DISC - DIAMETER (mm)
FIG. 4. Correlation of results of 30 ,ug disc and tube-dilution sensitivities of cepha-
lexin against gram-negative bacteria.
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muscular administration of cephalothin; it is far in excess of the barely
measurable serum levels achieved with oral cephaloglycin.'
Eighty percent of an oral dose of cephalexin is excreted unchanged in the
urine in the first six hours after administration, resulting in urine concen-
trations of the drug in the order of 800 Ftg/ml.' The high serum levels
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achieved with oral cephalexin provide this drug with a therapeutic potential
for systemic as well as urinary tract infections.
Cephalexin has been used successfully in Pneumococcal and Staphylococ-
cal pneumonias and in sepsis due to a variety of gram-positive and gram-
negative organisms.' That cephalexin can halt such infections is valuable
information, but life threatening infections in acutely ill patients are more
often treated with parenteral antibiotics. The present study examines the
efficacy of cephalexin in the treatment of skin and urinary tract infections,
clinical conditions in which oral antibiotics are commonly employed.
Results of our cephalexin studies showed that the outcome of therapy in
patients with urinary tract infections is influenced by the presenceorabsence
of structural abnormalities of the urinary tract, a finding consistent with
the behavior of other drugs. Seventy percent of patients with no structural
urinary tract abnormalities were cured with cephalexin therapy while only
8%o of those with such abnormalities were cured. Fass, et al.,@ and Levinson,
et al.,10 noted the same association of urinary tract abnormalities with the
therapeutic efficacy of cephalexin.
In the present study, cephalexin therapy cured skin infections in three
patients. Similar results have been observed by Fass and colleagues who
noted cures in 24 of 29 infections of the skin and soft tissue in their clinical
trials.
Our in vitro studies showed cephalexin to be effective at clinically achiev-
able concentrations against all strains of Staphylococcus, except for a few
strains of Staphylococcus albus, an organism whose multiple drug resistance
has been previously noted.'
Among the gram-negative organisms most strains of Klebsiella, E. coli,
and Proteus mirabilis were inhibited by concentrations of cephalexin ap-
proaching maximum serum levels. Urinary infections with these organisms
could easily be treated, but systemic infections might be expected to respond
less well unless the organism was a particularly sensitive one.
In general Enterococci, Enterobacter, indole positive Proteus, Pseudo-
monas and Serratia strains were only sensitive to very high levels of cepha-
lexin. Infections with most strains of these organisms are unlikely to re-
spond to cephalexin although in the present series a urinary infection with
Enterobacter and one with enterococcus were both treated successfully with
the drug.
Although no attempt was made to compare the effectiveness of cephalexin
with other oral antibiotics commonly used in the treatment of urinary tract
infections, the cure rate was similar to that observed in studies with sul-
fonamides or ampicillin in patients without structural abnormalities of the
urinary tract. Cephalexin offers no definite advantage over other agents
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but it does provide an alternate drug in treating urinary tract infections
caused by organisms resistant to the antibiotics commonly employed in
these infections. Cephalexin may also be useful in treating such infections
in patients allergic to other antimicrobial agents.
The in vitro spectrum of cephalexin, the evidence of clinical efficacy and
the lack of toxic side effects in this series and others suggest that cephalexin
may be a valuable agent in the treatment of a variety of infections requiring
oral therapy.
SUMMARY
Oral cephalexin was used to treat 22 urinary tract infections, three skin
infections and one case of osteomyelitis. The drug was effective in treating
infections in anatomically normal urinary tracts but not in deformed or
obstructed urinary tracts. Infections of the skin were cured. The effect of
cephalexin on the one bone infection could not be properly evaluated.
In vitro tests showed the drug inhibited growth of most strains of Staphy-
lococcus aureus, Staphylococcus albus, Klebsiella, E. coli and indole negative
Proteus, at clinically achievable serum levels. Enterococci, Enterobacter,
indole positive Proteus, Pseudomonas and Serratia strains were usually not
inhibited by drug levels attainable in the serum.
A zone of growth inhibition of 16 mm. or more around a30,ugcephalexin
disc was a good indication of drug sensitivity except with indole negative
Proteus and Klebsiella where false negative and false positive tests, respec-
tively, occurred.
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